Teleflex Yönetim

Yönetim kriter kontrolleri 3/4

Teleflex CEO'su Liam Kelly, May2016 tarihinde atandı, in görev süresi 8.08 yıldır. in toplam yıllık tazminatı $ 9.04M olup, şirket hissesi ve opsiyonları dahil olmak üzere 11.7% maaş ve 88.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.059% ine doğrudan sahiptir ve bu hisseler R$ 31.00M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.2 yıl ve 6.4 yıldır.

Anahtar bilgiler

Liam Kelly

İcra Kurulu Başkanı

US$9.0m

Toplam tazminat

CEO maaş yüzdesi	11.7%
CEO görev süresi	8.1yrs
CEO sahipliği	0.06%
Yönetim ortalama görev süresi	4.2yrs
Yönetim Kurulu ortalama görev süresi	6.4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Liam Kelly'un ücretlendirmesi Teleflex'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2024	n/a	n/a	US$296m
Dec 31 2023	US$9m	US$1m	US$358m
Oct 01 2023	n/a	n/a	US$405m
Jul 02 2023	n/a	n/a	US$369m
Apr 02 2023	n/a	n/a	US$363m
Dec 31 2022	US$8m	US$1m	US$363m
Sep 25 2022	n/a	n/a	US$412m
Jun 26 2022	n/a	n/a	US$510m
Mar 27 2022	n/a	n/a	US$488m
Dec 31 2021	US$9m	US$982k	US$485m
Sep 26 2021	n/a	n/a	US$434m
Jun 27 2021	n/a	n/a	US$351m
Mar 28 2021	n/a	n/a	US$280m
Dec 31 2020	US$6m	US$943k	US$336m
Sep 27 2020	n/a	n/a	US$367m
Jun 28 2020	n/a	n/a	US$479m
Mar 29 2020	n/a	n/a	US$551m
Dec 31 2019	US$7m	US$869k	US$462m
Sep 29 2019	n/a	n/a	US$442m
Jun 30 2019	n/a	n/a	US$269m
Mar 31 2019	n/a	n/a	US$183m
Dec 31 2018	US$6m	US$846k	US$196m
Sep 30 2018	n/a	n/a	US$66m
Jul 01 2018	n/a	n/a	US$89m
Apr 01 2018	n/a	n/a	US$170m
Dec 31 2017	US$3m	US$617k	US$155m

Tazminat ve Piyasa: Liam 'nin toplam tazminatı ($USD 9.04M ), BR pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.40M ).

Tazminat ve Kazançlar: Liam 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Liam Kelly (57 yo)

8.1yrs

Görev süresi

US$9,039,947

Tazminat

Mr. Liam J. Kelly has been Chief Executive Officer at Teleflex Incorporated since January 01, 2018 and has been its Director since May 4, 2018. He serves as Independent Director of Enovis Corporation (form...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Liam Kelly	Chairman	8.1yrs	US$9.04m	0.059% R$ 31.0m
Thomas Powell	Executive VP & CFO	12.3yrs	US$3.53m	0.022% R$ 11.7m
Daniel Logue	Corporate VP	3.4yrs	US$1.81m	0.021% R$ 11.1m
Jay White	Corporate VP & President of Global Commercial	3.3yrs	US$2.37m	0.0070% R$ 3.6m
John Deren	Corporate VP & Chief Accounting Officer	7.1yrs	Veri yok	0.0042% R$ 2.2m
Timothy Duffy	VP & Chief Information Officer	no data	Veri yok	Veri yok
Howard Cyr	Corporate VP & Chief Compliance Officer	2.6yrs	Veri yok	Veri yok
Cameron Hicks	Corporate VP & Chief Human Resources Officer	11.2yrs	US$1.34m	0.016% R$ 8.4m
James Ferguson	President & GM of Surgical	no data	Veri yok	Veri yok
Michelle Fox	Corporate VP & Chief Medical Officer	4.4yrs	Veri yok	Veri yok
Matthew James	President	4yrs	Veri yok	Veri yok
Jake Newman	President of The Americas	3.3yrs	Veri yok	Veri yok

4.2yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: T1FX34 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Liam Kelly	Chairman	6.1yrs	US$9.04m	0.059% R$ 31.0m
John Heinmiller	Independent Director	5.4yrs	US$308.20k	0.0060% R$ 3.1m
Gretchen Frances Haggerty	Independent Director	7.8yrs	US$308.20k	0.0076% R$ 4.0m
Stuart Randle	Independent Director	15.1yrs	US$324.53k	0.0092% R$ 4.8m
Andrew Krakauer	Independent Director	6.4yrs	US$303.28k	0.0084% R$ 4.4m
Stephen Klasko	Independent Lead Director	16.1yrs	US$350.30k	0.029% R$ 14.9m
Candace Duncan	Independent Director	9.1yrs	US$331.70k	0.0075% R$ 3.9m
Jaewon Ryu	Independent Director	1.1yrs	US$364.30k	Veri yok
Neena Patil	Independent Director	2.2yrs	US$301.20k	0.00085% R$ 443.1k

6.4yrs

Ortalama Görev Süresi

68yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: T1FX34 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.4 yıldır).

Teleflex Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Teleflex Incorporated, Annual General Meeting, May 03, 2024

Teleflex Incorporated, Annual General Meeting, Apr 29, 2022

Teleflex Incorporated Announces Board Changes

Recent updates

Teleflex Incorporated Revises Earnings Guidance for the Year 2024

Teleflex Incorporated Announces Quarterly Dividend, Payable December 16, 2024

Teleflex Incorporated Announces First Patient Enrolled Barrigel™ Rectal Spacer Trial for Post Radical Prostatectomy Radiation Therapy

Teleflex Incorporated Launches Next-Generation Arrow VPS Rhythm DLX Device and NaviCurve Stylet in Canada

Teleflex Incorporated Announces the Presentation of Data Supporting the Safety and Efficacy of Barrigel Rectal Spacer

Teleflex Incorporated Revises Earnings Guidance for the Full Year 2024

Teleflex Incorporated Expands Intraosseous Vascular Access Portfolio with New Arrow™ EZ-IO™ Intraosseous Access Procedure Tray

Teleflex Incorporated Announces Quarterly Cash Dividend, Payable on June 14, 2024

Teleflex Incorporated Raises Earnings Guidance for the Full Year 2024

Teleflex Incorporated, Annual General Meeting, May 03, 2024

Teleflex Incorporated Announces Quarterly Dividend, Payable on March 15, 2024

Teleflex Incorporated Offers Its Titan SGS Stapler with Staple Line Reinforcement

Teleflex Incorporated Announces First Patient Enrollment in ACCESS-MANTA Registry

Teleflex Incorporated Announces A New Peer-Reviewed Study in the Nature Journal Prostate Cancer and Prostatic Diseases Confirms the Position of the UroLift System as the Gold Standard in Minimally Invasive Surgical Treatment

Teleflex Incorporated Provides Earnings Guidance for the Full Year 2023

Teleflex Incorporated (NYSE:TFX) acquired Palette Life Sciences for $650 million.

Teleflex Incorporated (NYSE:TFX) acquired Palette Life Sciences for $650 million.

Teleflex Incorporated Announces Extension of Arrow ErgoPack Complete System to Hemodialysis and Large Bore Central Venous Catheters

Teleflex Incorporated Updates Earnings Guidance for the Year 2023

Teleflex Incorporated Receives FDA Clearance for Expanded Indication for QuikClot Control+(TM) Hemostatic Device Usage in Cardiac Surgical Procedures

Teleflex Incorporated (NYSE:TFX) entered into a definitive agreement to acquire Palette Life Sciences AB for $650 million.

Teleflex Incorporated (NYSE:TFX) entered into a definitive agreement to acquire Palette Life Sciences AB from Östersjöstiftelsen, Endowment Arm, Praktikerinvest AB and Recipharm Venture Fund AB for $650 million.

Teleflex Incorporated Receives FDA Clearance for the Wattson Temporary Pacing Guidewire

Teleflex Incorporated Announces the Arrow(R) EZ-Io(R) Needle Is Now FDA Cleared for Use in an MRI Environment

Teleflex Announces Quarterly Dividend, June 15, 2023

Teleflex Incorporated Provides Earnings Guidance for the Year 2023

Teleflex Incorporated Announces Worldwide Recall of Affected Lots of Gibeck Iso-Gard Filter Products

Teleflex Incorporated Revises Earnings Guidance for the Year 2022

Teleflex Incorporated (NYSE:TFX) completed the acquisition of Standard Bariatrics, Inc.

Teleflex Incorporated Launches New Arrow® Pressure Injectable Midline Catheter Portfolio

Teleflex Incorporated (NYSE:TFX) entered into a definitive agreement to acquire Standard Bariatrics, Inc. for $300 million.

Teleflex Incorporated Provides Earnings Guidance for the Full Year of 2022

Teleflex Incorporated (NYSE:TFX) acquired unknown stake in Traverse Vascular Inc.

Teleflex Incorporated Announces First Patient Enrollment in MANTA Ultra Study

Teleflex Launches New Arrow Pressure Injectable Midline Catheter in Australia and New Zealand

Teleflex Incorporated Launches New Arrow Pressure Injectable Midline Catheter in Europe, the Middle East and Africa Region

Teleflex Incorporated Reaffirms Earnings Guidance for the Full Year of 2022

Teleflex Incorporated Announces Regulatory Clearance for Its Urolift® System in China for the Treatment of Benign Prostatic Hyperplasia

Teleflex Announces Health Canada Approval of MANTA® Vascular Closure Device

Teleflex Incorporated Declares Quarterly Cash Dividend, Payable on June 15, 2022

Teleflex Announces the Launch of the UroLift® System in Japan for the Treatment of Benign Prostatic Hyperplasia

Teleflex Incorporated, Annual General Meeting, Apr 29, 2022

Teleflex Incorporated Announces Board Changes

Teleflex Incorporated Declares Quarterly Cash Dividend, Payable March 15, 2022

Teleflex Receives FDA Clearance for Expanded Indication for Specialty Catheter and Coronary Guidewire Use in CTO PCI Procedures

Teleflex Announces Large-Scale Analysis of Real-World Healthcare Claims Data for Enlarged Prostate Procedures At the American Urological Association 2021 Annual Meeting

Teleflex Unveils the UroLift Advanced Tissue Control System and the UroLift 2 System

Teleflex Incorporated Announces New Study Provides Insights into the Biocompatibility and Durability of the UroLiftSystem in Improving Benign Prostatic Hyperplasia Symptoms

Medline Industries, Inc. completed the acquisition of Certain product lines of global respiratory product portfolio of Teleflex Incorporated.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş